Table 2.

Summary of results for systemic therapy of neuroendocrine tumour liver metastases.

Modality author [Ref]	Intervention	Number of patients	Overall survival (5  years)	Median survivals (months)	Progression/disease-free survival	Clinical response	Biochemical response	Radiological response
Biological Therapy
Ducreux et al. [26]	Lantreotide	46						5%
Aparicio et al. [27]	Octreotide	35			11 months			3% (57%  stabilised)
Rinke et al. [28]	Octreotide LAR	85			14.3 months			67% stabilised
Oberg and Eriksson [29]	IFN α	111		>80	34 months	68%	42%	15% (39%  stabilised)
Arnold et al. [30]	Octreotide ± IFN α	109		32 versus 54 (combined)				1.9% (27%  stabilised)
Fjällskog et al. [31]	Somatostatin ± IFN α	16					62.5%	19%
Chemotherapy
Moertel et al. [32]	STZ + doxorubicin	36		26	20 months			69%
	STZ + 5FU	33		18	6.9 months			45%
Turner et al. [33]	5FU + cisplatin + STZ	79		31.5	9.1 months			33%
Sun et al. [34]	STZ + doxorubicin	85		15.7	4.5 months			15.9%
	STZ + 5FU	78		24.3	5.3 months			16%
Kouvaraki et al. [35]	5FU + doxorubicin + STZ	61	74% (2 yrs)		41% (2  years)
Strosberg et al. [36]	Temolozomide + capecitabine	30	92% (2 yrs)		18 months			70%
Moertel et al. [37]	Etoposide + cisplatin	18		19	8 months			67%
Molecular-targeted therapy
Raymond et al. [38]	Sunitinib	171			11.4 months			9.3%
Yao et al. [39]	Everolimus	410	34% (1.5 yrs)		11 months
Yao et al. [40]	Bevacizumab	44			95% (18  weeks)
PPRT
Cwikla et al. [41]	DOTATATE Y-90	60		22	17 months	72%		23%
Kwekkeboom et al. [42]	177Lu-octreotate	131			>36 months			28%
Pfeifer et al. [43]	Y-DOTATOC or 177Lu-DOTATOC	69			29 months			23.6%
Kwekkeboom et al. [44]	177Lu-DOTA 0,Tyr3	310		46	40 months			30%